TELIGENT, INC. (NASDAQ:TLGT) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Officers of Teligent, Inc. (the Company) will present an investor
presentation to members of the investment community beginning on
Wednesday, January 11, 2017. A copy of the investor presentation
to be used during these programs is attached to this Current
Report on Form 8-K as Exhibit 99.1 and is also available in the
Investors section of the Companys website
atwww.teligent.com.
In accordance with General Instruction B.2 on Form 8-K, the
information set forth in this Item 7.01 and the investor
presentation attached to this report as Exhibit 99.1 is furnished
and shall not be deemed to be filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section, nor shall such
information be deemed incorporated by reference in any filing
under the Securities Exchange Act of 1934, as amended, or the
Securities Act of 1933, as amended.
The investor presentation attached hereto as Exhibit 99.1
contains certain statements that may be deemed to be
forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. In some cases, these forward-looking
statements can be identified by the use of forward-looking
terminology, including the terms believes, estimates,
anticipates, expects, plans, intends, may, could, might, will,
should, approximately or, in each case, their negative or other
variations thereon or comparable terminology, although not all
forward-looking statements contain these words. They appear in a
number of places throughout the presentation and include
statements regarding our intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things, our inability to meet current or future regulatory
requirements in connection with existing or future Abbreviated
New Drug Applications (ANDAs); our inability to achieve
profitability; our failure to obtain U.S. Food and Drug
Administration (FDA) approvals as anticipated; our inability to
execute and implement our business plan and strategy; the
potential lack of market acceptance of our products; our
inability to protect our intellectual property rights; changes in
global political, economic, business, competitive, market and
regulatory factors; and our inability to complete successfully
future product acquisitions.
By their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive
dynamics, and healthcare, regulatory and scientific developments
and depend on the economic circumstances that may or may not
occur in the future or may occur on longer or shorter timelines
than anticipated. Although we believe that we have a reasonable
basis for each forward-looking statement contained in the
presentation, we caution you that forward-looking statements are
not guarantees of future performance and that our actual results
of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ
materially from the forward-looking statements contained in the
presentation as a result of, among other factors, the factors
referenced in the Risk Factors section of our Annual Report on
Form 10-K filed with the Securities and Exchange Commission on
March 15, 2016 and the Risk Factors sections of our Quarterly
Reports on Form 10-Q filed with the Securities and Exchange
Commission on May 10, 2016, August 8, 2016 and November 8, 2016,
respectively.
In addition, even if our results of operations, financial
condition and liquidity, and the development of the industry in
which we operate are consistent with the forward-looking
statements contained in the presentation, they may not be
predictive of results or developments in future periods. Any
forward-looking statements that we make in the presentation speak
only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of the presentation, except as
required by law.
You should read carefully our Forward-Looking Statements and the
factors described in the Risk Factors sections of our Annual
Report on Form 10-K to better understand the risks and
uncertainties inherent in our business.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description | ||
| 99.1 | Investor Presentation | ||
About TELIGENT, INC. (NASDAQ:TLGT)
Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It has two platforms: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. Its pipeline includes over 30 Abbreviated New Drug Applications filed with the United States Food and Drug Administration for additional pharmaceutical products. It holds additional over 40 product candidates at various stages of its development pipeline, 10 of which are on stability testing. TELIGENT, INC. (NASDAQ:TLGT) Recent Trading Information
TELIGENT, INC. (NASDAQ:TLGT) closed its last trading session 00.00 at 7.02 with 122,627 shares trading hands.